A large number of reversible LSD1 inhibitors are developed;727 two of them, CC-90011 (substrate competitive inhibitor)734 and SP2577 (allosteric inhibitor)735 have entered clinical trials for therapy of cancers including sarcomas, non-Hodgkin’s lymphomas, and small cell lung cancer (Table 1). Here, KDM1A is linked to cancer.